Long-term Follow-up of HIV Infected Patients Identified During Early Infection
Acute HIV Infection and Early Disease Research Program (AIEDRP) CORE01 Database
2 other identifiers
observational
157
5 countries
30
Brief Summary
This is a long-term follow-up study of people who are identified during acute or recent HIV infection and are being followed at clinical research sites associated with the Acute HIV Infection and Early Disease Research Program (AIEDRP).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jul 2003
Typical duration for all trials
30 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2003
CompletedFirst Submitted
Initial submission to the registry
June 30, 2004
CompletedFirst Posted
Study publicly available on registry
July 1, 2004
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2007
CompletedOctober 29, 2012
October 1, 2012
June 30, 2004
October 26, 2012
Conditions
Keywords
Eligibility Criteria
You may qualify if:
- Documented acute or recent HIV infection
- Willing to allow study investigators access to and use of participant's medical information from other AIEDRP clinical trials
- Parent or guardian willing to provide informed consent, if applicable
- If enrolled at an AIDS Clinical Trial Group (ACTG) site, must also be participating in one of the following clinical trials: AIN501/ACTG A5216, AIN503/ACTG A5217, or AIN504/ACTG A5218
You may not qualify if:
- More than 7 days of antiretroviral therapy prior to study entry without adequate documentation of pretreatment viral load and CD4 count. Individuals who have failed postexposure prophylaxis with antiretroviral treatment are not excluded from enrollment.
- Any factor that, in the opinion of the study official, may interfere with study participation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (30)
University of Alabama - Birmingham
Birmingham, Alabama, 35294, United States
Cedars-Sinai
Los Angeles, California, 90048, United States
University of California, San Diego
San Diego, California, 92103, United States
University of California, San Francisco
San Francisco, California, 94143, United States
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
Torrance, California, 90502, United States
University of Colorado Health Sciences Center
Denver, Colorado, 80262, United States
Johns Hopkins University
Baltimore, Maryland, 21218, United States
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Fenway Community Health
Boston, Massachusetts, 02115, United States
Community Research Initiative of New England-Sprin
Springfield, Massachusetts, 01107, United States
Washington University (St. Louis)
St Louis, Missouri, 63108-2138, United States
State University of NY Downstate
Brooklyn, New York, 11203, United States
Beth Israel Medical Center
New York, New York, 10003, United States
Aaron Diamond AIDS Research Center
New York, New York, 10016, United States
Columbia University
New York, New York, 10027, United States
Community Health Network, Inc.
Rochester, New York, 14642-0001, United States
University of Rochester Medical Center
Rochester, New York, 14642-0001, United States
University of North Carolina, Chapel Hill
Chapel Hill, North Carolina, 27599-7215, United States
Duke University
Durham, North Carolina, 27701, United States
Presbyterian Medical Center - Univ. of PA
Philadelphia, Pennsylvania, 19104, United States
University of Pennsylvania, Philadelphia
Philadelphia, Pennsylvania, 19104, United States
Vanderbilt University
Nashville, Tennessee, 37212, United States
University of New South Wales
Darlinghurst, New South Wales, 2010, Australia
Prahran Market Clinic
St Kilda, Victoria, 3182, Australia
The Centre Clinic
St Kilda, Victoria, 3182, Australia
Carlton Clinic
Carlton VID, 3053, Australia
Centro de Referencia Estadual de AIDS (CREAIDS)
Salvador, Estado de Bahia, 40110-160, Brazil
University of British Columbia, Vancouver, BC
Vancouver, British Columbia, V6Z 2C7, Canada
Montreal Chest Institute of the McGill University
Montreal, Quebec, H2W 1T7, Canada
University of Zimbabwe Clinical Research Centre
Harare, Zimbabwe
Related Publications (3)
Kassutto S, Rosenberg ES. Primary HIV type 1 infection. Clin Infect Dis. 2004 May 15;38(10):1447-53. doi: 10.1086/420745. Epub 2004 Apr 30.
PMID: 15156484BACKGROUNDPilcher CD, Eron JJ Jr, Galvin S, Gay C, Cohen MS. Acute HIV revisited: new opportunities for treatment and prevention. J Clin Invest. 2004 Apr;113(7):937-45. doi: 10.1172/JCI21540.
PMID: 15057296BACKGROUNDFalster K, Gelgor L, Shaik A, Zablotska I, Prestage G, Grierson J, Thorpe R, Pitts M, Anderson J, Chuah J, Mulhall B, Petoumenos K, Kelleher A, Law M. Trends in antiretroviral treatment use and treatment response in three Australian states in the first decade of combination antiretroviral treatment. Sex Health. 2008 Jun;5(2):141-54. doi: 10.1071/sh07082.
PMID: 18588779RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Martin Markowitz, MD
Aaron Diamond AIDS Research Center, Rockefeller University
- STUDY CHAIR
Susan Little, MD
University of California, San Diego